Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tissue-directed pharmacokinetics.

J J Schentag1, C H Ballow

  • 1State University of New York, Buffalo 14209.

The American Journal of Medicine
|September 12, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of organism species on microbial eradication and development of resistance in severe gram-negative pneumonia.

Journal of chemotherapy (Florence, Italy)·2010
Same author

Pharmacokinetics of Oral Azithromycin in Serum, Urine, Polymorphonuclear Leucocytes and Inflammatory vs Non-Inflammatory Skin Blisters in Healthy Volunteers.

Clinical drug investigation·2008
Same author

A case series of macrolide treatment failures in community acquired pneumonia.

Journal of chemotherapy (Florence, Italy)·2007
Same author

Pharmacokinetic and pharmacodynamic modelling of antibiotic therapy.

Current opinion in infectious diseases·2006
Same author

Linezolid in the treatment of osteomyelitis: results of compassionate use experience.

Infection·2004
Same author

Pharmacokinetics and metabolism of moxifloxacin.

Drugs of today (Barcelona, Spain : 1998)·2003
Same journal

Mineralocorticoid Antagonists for Post-MI HFpEF: Plausible Biology Meets Low Residual Risk?

The American journal of medicine·2026
Same journal

GLP-1 Receptor Agonists and Age-related Macular Degeneration Risk in Diabetes or Non-diabetic Obesity: A Retrospective Cohort Study.

The American journal of medicine·2026
Same journal

Marijuana Use and Acute Myocardial Infarction: Mechanistic Insights, Clinical Implications, and Emerging Challenges.

The American journal of medicine·2026
Same journal

Cave Canem - Beware of the Dog.

The American journal of medicine·2026
Same journal

Risk Factors for 30-day Hospital Readmission After Hospital-at-Home Treatment of Acute Pyelonephritis.

The American journal of medicine·2026
Same journal

Mesenteric panniculitis.

The American journal of medicine·2026
See all related articles

Azalide antibiotics like azithromycin distribute extensively into tissues, concentrating in immune cells. This unique pharmacokinetic profile allows for convenient once-daily dosing and sustained therapeutic drug levels at infection sites.

Area of Science:

  • Pharmacology
  • Microbiology
  • Drug Discovery

Background:

  • Conventional oral antibiotics exhibit rapid serum elimination and limited intracellular penetration.
  • Understanding novel antibiotic distribution is crucial for optimizing treatment strategies.

Purpose of the Study:

  • To characterize the distinct pharmacokinetics of azalide antibiotics, specifically azithromycin.
  • To elucidate the drug's movement between serum, interstitial, and intracellular compartments.

Main Methods:

  • Pharmacokinetic analysis of azithromycin absorption, distribution, and elimination.
  • Investigation of drug concentration in various tissue compartments and immune cells.

Main Results:

  • Azithromycin demonstrates rapid and extensive intracellular penetration, concentrating within phagocytes.

Related Experiment Videos

  • High azithromycin concentrations are achieved in pulmonary, genital, and lymphatic tissues.
  • A terminal half-life of approximately 60 hours allows for once-daily administration.

    • Conclusions:

    • Azalide pharmacokinetics, exemplified by azithromycin, differ significantly from conventional antibiotics.
    • Extensive tissue distribution and intracellular accumulation support prolonged therapeutic effects.
    • Therapeutic levels are maintained for 4-7 days post-treatment, enabling less frequent dosing.